DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for endodermal sinus tumor — screening already-approved drugs against its 17-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEndodermal sinus tumor maps to a 17-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for endodermal sinus tumor is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
KRas proto-oncogene, GTPase (KRAS) — KRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7VVB · 1.7 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
A 1991 case report describes a patient with a pineal endodermal sinus tumour who was free of disease two years after surgery, adjuvant chemotherapy, and craniospinal irradiation. The authors note that such an outcome is very unusual and recommend a multidisciplinary approach with chemotherapy as adjuvant treatment. A 2007 report of an isolated orbital endodermal sinus tumour in a one-year-old boy states that after diagnosis by serology and histopathology, the patient underwent chemotherapy. The authors list treatment options as surgical removal and chemotherapy, but give no survival or response data for this single case.
A 1987 paper reports that combination chemotherapy with cisplatin, vinblastine, and bleomycin (PVB) is considered best for disseminated non-seminomatous germ cell tumours, with a 70% long-term disease-free survival rate. However, for patients with primary mediastinal endodermal sinus tumours, results with PVB have been disappointing, and more intensive regimens with major toxicity have been proposed. The authors describe one patient who, after standard PVB chemotherapy, became one of the longest reported survivors of mediastinal endodermal sinus tumours. They conclude that optimal chemotherapy for endodermal sinus tumours is yet to be determined.
Across these three reports, no randomised trial data exist. The evidence rests on single cases and small series. The 1987 paper explicitly states that standard PVB results are disappointing for mediastinal endodermal sinus tumours, and the 1991 paper calls its own success very unusual. No abstract reports a consistent, reproducible treatment outcome for this rare tumour.
What is still missing is any prospective trial, any standardised regimen tested in more than a handful of patients, and any understanding of which patients might benefit from more intensive versus standard chemotherapy. Without funding for multicentre collaboration, the rarity of the tumour will continue to limit evidence to isolated case reports.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of neurosurgery · 1991 · 26 citations
Successful treatment of a pineal endodermal sinus tumor
AbstractA patient with a pineal endodermal sinus tumor is presented who was successfully treated by a combination of surgery, adjuvant chemotherapy, and craniospinal irradiation. Two years after diagnosis, he is free of any disease. A review of the literature shows that such an outcome is very unusual. A multidisciplinary treatment is recommended for this rare tumor, using chemotherapy as adjuvant treatment.
Ophthalmic Plastic and Reconstructive Surgery · 2007 · 13 citations
Isolated Orbital Endodermal Sinus Tumor
AbstractIn Brief Purpose: To describe the clinical, serologic, histopathologic, and immunohistochemical findings of an isolated endodermal sinus tumor of the orbit in a 1-year-old boy. Methods: A retrospective case report and literature review. Results: The patient was managed by the ophthalmology and oncology services. After the diagnosis was established by serologic analysis and histopathology, the patient underwent chemotherapy. Conclusions: Endodermal sinus tumor is a malignant germ-cell tumor that usually involves the gonadal tissue. Primary extragonadal sites occur rarely, and include the orbit. Treatment options include surgical removal and chemotherapy. The authors report a case of malignant extragonadal germ-cell tumor, and review the literature on this rare neoplasm.
Australian and New Zealand Journal of Medicine · 1987 · 1 citations
PROLONGED SURVIVAL WITH CONVENTIONAL CISPLATINUM/VINBLASTINE/BLEOMYCIN THERAPY ALONE FOR MEDIASTINAL ENDODERMAL SINUS TUMOUR
AbstractCombination chemotherapy with cisplatin, vinblastine, and bleomycin (PVB) is considered to be the best treatment for disseminated non-seminomatous germ cell tumours, with a 70% long term disease-free survival rate. For one subgroup of patients, those with primary mediastinal endodermal sinus tumours, results with PVB have been disappointing and more intensive regimens with major toxicity have recently been proposed. We report a patient who, following standard PVB chemotherapy, is one of the longest reported survivors of mediastinal endodermal sinus tumours. Optimal chemotherapy for endodermal sinus tumours is yet to be determined.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
